InnoStar announces the operational launch of its Nantong Phase II High-Quality Non-Clinical Evaluation Platform in China. This 24,000 sqm facility in Haimen District features 130 international-standard animal housing rooms, addressing critical capacity constraints to accelerate complex drug development programs. Core Service Enhancements: Advanced Modality Support: Enhanced capabilities for Innovative Molecules, ATMPs/CGT, & Complex Formulations. Integrated Solutions: Synergy with specialty platforms (Radiology Imaging, Ophthalmic Drugs, Organoid Tech).  Multi-Site Agility: Accelerated project initiation via China-wide facility network. The expansion strengthens InnoStar’s end-to-end preclinical offerings, meeting growing global demand for integrated CRO solutions. Partners gain access to scaled, GLP-compliant resources for high-stakes therapeutic programs. InnoStar: Powering confident decisions from discovery to preclinical.